Hikma Pharmaceuticals Stock

GBP18.36

0.82%

London, Aug 22, 05:35 pm CET

ISIN

GB00B0LCW083

Symbol

HIK

Index

FTSE 100, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

Hikma Pharmaceuticals Stock price

GBP18.36

-2.25 10.93% 5Y

London, Closing price Fri, Aug 22 2025

+0.15 0.82%

ISIN

GB00B0LCW083

Symbol

HIK

Index

FTSE 100, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

GBP4.0b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

14.9 | 10.6

P/S

1.7 | 1.6

EV/Sales

- | -

EV/FCF

P/B

Dividends

DPS

GBP0.61

Yield 1Y | 5Y

3.3% | 2.5%

Growth 1Y | 5Y

24.3% | 12.6%

Payout 1Y | 3Y

51.6% | 62.6%

Increased

19 Years

Financials (TTM | estimate)

Revenue

GBP2.4b | GBP2.5b

EBITDA

GBP512.5m | GBP665.8m

EBIT

GBP445.2m | GBP560.3m

Net Income

GBP274.4m | -

Free Cash Flow

GBP168.6m

Growth (TTM | estimate)

Revenue

7.5% | 8.4%

EBITDA

-2.0% | 24.9%

EBIT

-2.4% | 20.5%

Net Income

30.2% | -

Free Cash Flow

-39.8%

Financial Health

Equity Ratio

45.0%

Return on Equity

15.5%

ROCE

ROIC

Debt/Equity

EPS

GBP1.2

FCF per Share

Short interest

50.0%

Employees

10k

Rev per Employee

GBP250.0k

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

??

20 Analysts have issued a Hikma Pharmaceuticals forecast:

16x Buy

80%

4x Hold

20%

More details on Analyst Estimates Including Price Targets

20 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	2,399 2,399	8% 8% 100%
- Direct Costs	1,352 1,352	15% 15% 56%
Gross Profit	1,047 1,047	1% 1% 44%
- Selling and Administrative Expenses	419 419	0% 0% 17%
- Research and Development Expense	113 113	5% 5% 5%
EBITDA	512 512	2% 2% 21%
- Depreciation and Amortization	67 67	1% 1% 3%
EBIT (Operating Income) EBIT	445 445	2% 2% 19%
Net Profit	274 274	30% 30% 11%

In millions GBP.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Riad Mishlawi
Employees	9,500
Founded	1978
Website	www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now